Lactase-Assisted Control Trial On Weight GAin in INfants.

Lactose, a disaccharide that includes the monosaccharides glucose and galactose, is the main carbohydrate found exclusively in mammalian milk. The absorption of lactose requires lactase activity to break the bond that binds the 2 monosaccharides. Lactase is found in the intestinal mucosa and is located at the ends of the villi, while it is a factor of maximum clinical importance in milk tolerance and in the occurrence of diarrheal disease.

Milk intolerance can be attributed to either lactose or protein content. Lactose intolerance may occur in infants and young children with acute diarrhoea, although its clinical significance is limited. Lactose intolerance symptoms are relatively common among older children and adolescents. However, associated intestinal damage is rarely observed. Lactose tolerance is a separate entity from cow's milk protein allergy, which is of immune etiology and can cause varying degrees of intestinal mucosal injury. Cow's milk protein intolerance is reported in 2% to 5% of infants within the first 1 to 3 months of life, usually subsides by the age of 1 year and is not the subject of this statement.

In more specific cases, the hydrogen breath test is the least invasive and most helpful test for diagnosing lactose malabsorption. The test is performed by administering a standardized amount of lactose (2 g/kg, up to a maximum of 25 g, equivalent to the amount of lactose in 2 glasses of milk) after fasting overnight and then measuring the amount of hydrogen in the exhaled air for a period of 2 to 3 hours. An increase (20 ppm) in hydrogen after about 60 minutes is indicative of lactose malabsorption. Factors that may produce false negative or false positive results include conditions affecting the intestinal flora (e.g., recent use of antimicrobial agents), lack of hydrogen-producing bacteria (10%-15% of the population), ingestion of a high-fiber diet before testing, bacterial overgrowth of the small intestine, or intestinal motility disorders.

In newborns and infants with diarrhea in whom lactose (or other carbohydrate) intolerance is suspected, the stool can be checked for carbohydrate malabsorption by testing the pH of the stool, which is reduced by carbohydrate malabsorption as a result of the formation of volatile fatty acids. It is noted that the pH of the stool is lower in infants compared to older children and adolescents due to the normal overload of lactose in their diet; which in turn helps to promote the growth of Lactobacillus species in the large intestine. Reducing substances can also be detected in the stool, such as reducing sugars that include lactose, glucose, fructose and galactose, but not sucrose. Because some patients may only absorb enough carbohydrates, such as lactose, to lower the pH of the stool but not increase the excretion of carbohydrates in the stool, the pH test is a more sensitive test for carbohydrate malabsorption.

Developmental lactase deficiency is defined as the relative lactase deficiency observed in premature newborns less than 34 weeks of gestation. In the immature gastrointestinal tract, lactase and other disaccharidesas are deficient until at least 34 weeks of gestation. One study in premature babies reported a benefit from the use of lactase-supplemented foods or lactose-reduced preparations. While the use of lactose-containing preparations and human milk does not appear to have short- or long-term harmful effects on newborns and infants. Up to 20% of dietary lactose can reach the colon in newborns and young infants. The metabolism of lactose by colon microbes lowers the pH of the stool, which has a beneficial effect, favoring certain organisms (e.g. Bifidobacterium and Lactobacillus species) instead of potential pathogens (Proteus, Escherichia coli and Klebsiella species) in young infants.

Lactase is detected for the first time in the fetus from the 10th week of gestation. At 28 to 34 weeks, lactase activity is only ~30% of that found at the end of pregnancy. At 35 to 38 weeks, it reaches 70% of the activity of the end months. Due to the inadequate functional development of lactase, premature infants may not digest and absorb the main source of carbohydrate energy, lactose. The high osmotic load associated with indigestible lactose is one of the many possible causes of diarrhea and food intolerance in premature babies. As a result of diarrhea stools and small bowel damage, the already low functional activity of lactase will be further reduced affecting weight gain, while it takes up to 2 weeks for lactase activity to be restored.

Lactose intolerance is often treated with soy proteins, protein hydrolysis products, low-lactose, or lactose-free formulas. However, these types do not meet the nutritional requirements for the development and development of premature newborns, which need human milk with a human milk booster or premature milk. Ideally, premature babies with lactose intolerance should take these hydrolyzed lactose foods. Carlson et al showed that the addition of lactase to premature formula reduces the amount of lactose by 70% after a 2-hour incubation period at room temperature, with negligible effect on osmolarity. Previous studies have found that premature infants fed a reduced lactose formula had a better weight gain rate than those who took 100% lactose formula. In two of these studies, weight gain improved despite eating fewer calories.

In the present study we intend to test whether the use of lactase to hydrolysis lactose in premature milk would result in better weight gain and improved dietary tolerance by taking the same calorie intake.

METHOD Study Population A prospective, randomized controlled trial with caregivers and investigators responsible for outcome analysis and interpretation masked to treatment allocation will be conducted to evaluate feeding tolerance and weight gain in preterm infants receiving either (1) human milk or preterm formula supplemented with lactase (intervention group) or (2) human milk or preterm formula without lactase supplementation (non-intervention group).

Study Day 1 will be the day on which intestinal feeding will provide ≥75% of the daily intake of caloric needs. The study will be terminated when the newborn reaches 36 weeks or is discharged from the unit, whichever comes first.

Inclusion criteria The study will enrol newborns (1) with a gestational duration of 28 to 34 weeks, (2) who receive ≥75% of their energy needs intestinally, (3) with the absence of severe congenital malformations or gastrointestinal diseases, including necrotizing enterocolitis (NEC) (4) without taking postnatal steroids or diuretics at the time of eligibility assessment. Small, suitable and large for newborns of gestational age will be eligible for the study.

Exclusion criteria Exclusion criteria will be neonates whose guardians refuse to participate in the study, neonates with congenital malformations or gastrointestinal diseases, and neonates receiving postnatal steroids or diuretics.

Feeding newborns The feeding of the newborns of the study will be in accordance with the usual practices of the clinic, i.e. the first choice will be breast milk, the second the human milk of the donor from the milk bank and the third choice the formula of premature newborns. Breast milk fortifiers will be added to breast milk according to the usual clinic practices, i.e. when the volume of milk administered exceeds 25 ml per meal.

Human milk is given an estimated caloric value of 68 kcal/100 mL, while premature formula is given 81 kcal/100 mL.

Randomization Guardians of newborns who meet the criteria for inclusion in the study will be approached to be informed about participation in the study. Newborns whose guardians consent to participate will be included in the study.

Newborns, after enrolment in the study, will be randomized to either the lactase group or the control group. The results of randomization will not be known to the principal investigator until after the study is completed.

Intervention Newborns in the lactase group will receive milk fortified with 2 drops of lactase/kg of body weight per meal. The enrichment of the milk with lactase drops will be carried out by the nurse on duty without it being known by the principal investigator to which group (lactase group or control group) each newborn belongs. Only a secondary researcher and the shift nurse will have access to neonatal randomization information.

The lactase drops that will be used in the study will be Delictase®. The supply of Delictase® lactase preparations will be carried out by Prime Biosciences, every 2 months at the study site.

Recording of results For all newborns in the study, perinatal and neonatal data will be recorded on computers anonymously by the researchers. Somatometric data (body weight, head circumference, body length) will be recorded at birth and per week until the completion of the study. Biochemical markers of homeostasis (protein, albumin, sodium, and potassium) will also be recorded according to the usual practices of neonatal hospitalization in the NICU. Caloric intake and type of food will be recorded daily The main outcome variable will be daily weight-gain velocity from study entry to study completion, calculated for each infant as the difference between body weight at study completion and body weight on study day one divided by the number of study days.

Secondary outcomes will include head circumference and length gain velocities. Other prespecified outcomes will include abdominal distension, emesis, bowel-movement frequency, and serum total protein, albumin, sodium, and potassium concentrations. Gastric residual volume and stool reducing substances were prespecified feeding-tolerance measures but were not incorporated into prospective data collection and therefore were not available for analysis. Feeding-tolerance outcomes will include abdominal distension, emesis, and bowel-movement frequency. Abdominal distension will be recorded as the occurrence of clinically apparent abdominal distension at any time during the study period. For emesis, weekly incidence will be defined as the proportion of infants experiencing at least one day with >2 episodes within 24 hours during the respective study week. Bowel-movement frequency will be recorded as the number of bowel movements per day.

Serum protein, albumin, sodium, and potassium concentrations will be obtained according to routine clinical practice and will be also recorded. Finally, any withdrawal from the study due to feeding intolerance or NEC will be recorded.

Statistical analysis According to previous studies, the main outcome of the study (weight gain, g/day) was used as the basis for calculating the sample size. A total of 100 newborns (50 newborns per group) allows the detection of a 33% increase in mean weight gain per day in the treatment group, with a strength of 0.80. The differences between the groups are considered statistically significant at the level of P <.05.

Neonatal characteristics of the lactase and control group will be compared with the t-test in terms of continuous variables (caloric intake, weight gain, length, head circumference, gastric residual volume, daily number of vomiting episodes, daily stool count, and serum albumin, total protein, sodium, and potassium concentrations) or the Mann-Whitney test for variables with abnormal dispersion. The Pearson X2 or Fisher exact test will be used to compare the categorical variables (proportion of neonates in each group who developed food intolerance, had at least one episode of vomiting during the study, withdrew from the study due to medical condition or parental request, or experienced NEC) between the two groups.

Regression analysis will be used to check the correlation of weight gain with lactase administration or not, stratified for perinatal and neonatal factors with statistical significance.

Duration of the study Recruitment is expected to begin in August 2025 and be completed within 24 months.